27.35
+1.17(+4.47%)
Currency In USD
| Previous Close | 26.18 |
| Open | 26.01 |
| Day High | 27.37 |
| Day Low | 25.7 |
| 52-Week High | 27.8 |
| 52-Week Low | 12.72 |
| Volume | 1.8M |
| Average Volume | 1.8M |
| Market Cap | 4.79B |
| PE | -9.7 |
| EPS | -2.82 |
| Moving Average 50 Days | 24.64 |
| Moving Average 200 Days | 18.27 |
| Change | 1.17 |
If you invested $1000 in Immunovant, Inc. (IMVT) since IPO date, it would be worth $2,748.74 as of January 15, 2026 at a share price of $27.35. Whereas If you bought $1000 worth of Immunovant, Inc. (IMVT) shares 5 years ago, it would be worth $620.18 as of January 15, 2026 at a share price of $27.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immunovant Announces Pricing of $550 Million Common Stock Financing
GlobeNewswire Inc.
Dec 11, 2025 6:29 AM GMT
Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoim
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
GlobeNewswire Inc.
Oct 27, 2025 8:10 PM GMT
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire Inc.
Sep 03, 2025 4:57 PM GMT
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 les